Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada

Gelhorn, Heather L.; Garris, Cindy; Arthurs, Erin; Spinelli, Frank; Cutts, Katelyn; Chua, Gin Nie; Collacott, Hannah; Lebouché, Bertrand; Lowman, Erik; Rice, Howard; Heidenreich, Sebastian

doi:10.3390/jpm12030334

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A vast majority of the study population preferred the injectable ART to be administered every 8 weeks. This in concert with a discrete choice experiment among adult PLHIV in which the majority (59%) preferred the long-acting cabotegravir/rilpivirine injection as it overcomes treatment challenges, such as adherence and daily pill burden [45].…”

Section: Discussionmentioning

confidence: 98%

“…The instrument for this study is a validated two-sectioned questionnaire. The rst section obtained the basic Sociodemographic data and clinical information, while the second section part was used to assess the preferences of HIV regimen [29,30]. The HIV treatment satisfaction questionnaire was employed to assess satisfaction with current HIV regimen.…”

Section: Study Instrument and Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

HIV Treatment Satisfaction and Preferences for HIV regimen among Female Sex Workers

Haiwa,

Hedima,

Kalu

2024

Preprint

View full text Add to dashboard Cite

Improving patient satisfaction is a vital patient-reported outcome that can enhance healthcare services. There is considerable interest among patients, healthcare professionals, and policymakers in including patients in decision-making processes that affect their overall health. Female sex workers views about their HIV treatment may reflect their priorities that shape their overall quality of life. This study assessed the satisfaction with HIV treatment and preference for HIV regimen. This cross-sectional study comprised of 244 female sex workers who had been on combined antiretroviral therapy for a minimum of one year at the Society for Family Health (SFH) clinic in Mubi, Adamawa State Nigeria. HIV treatment satisfaction scores were also categorised in high (80–100), moderate (60–79) or low (< 60) according to Blooms cut-off points. Chi square test was applied to identify factors, if any, and that may explain association of HIV treatment satisfaction with sociodemographic data while binary logistic regression analysis was carried out to determine predictors of HIV treatment satisfaction. A p-value < 0.05 was considered statistically significant (95% Confidence Interval). The findings from this study showed that the majority of the patients, 140 (57.4%), were between the ages of 25 and 35 and had been on antiretroviral therapy (ART) for less than 3 years, 98 (40.2%), were diagnosed at the age of 18 to 25, 107 (43.9%), and started sex work at the same age, 146 (59.8%). Additionally, nearly half of the FSWs were involved in the use of other substances, 103 (42.2%). Two-thirds of the patients were not diagnosed with AIDS-related tuberculosis, 185 (75.8%), and nearly all were on the tenofovir/lamivudine/dolutegravir regimen, 214 (96.7%). Furthermore, more than two-thirds of the population had a suppressed viral load, 214 (87.7%), and had disclosed their HIV status, 126 (51.6%). While HIV treatment satisfaction is significantly associated with age at HIV diagnosis (p < 0.001), age at commencement of sex work (p = 0.01), highest level of education (p < 0.001), marital status (p < 0.001), use of substance (p < 0.001), HIV regimen at viral load (p < 0.001), virologic status p < 0.001) and HIV disclosure status (p < 0.001). This study also found age at HIV diagnosis (p = 0.005; AOR 0.24; 95% CI 0.09–0.66), lack of formal education (p = 0.02; AOR 0.43; 95%CI 0.20–0.92), married sex workers (p = 0.005; AOR 0.17; 95% CI 0.07–0.39), use of cigarette (p = 0.12–0.79; AOR 0.13; 95% CI 0.12–0.79) and other psychoactive substances (p = 0.005; AOR 0.19; 95% CI 0.09–0.39), unsuppressed virologic status (p = 0.001; AOR 0.07; 95% CI 0.01–0.31) and undisclosed HIV status (p = 0.007; AOR 0.37; 95% CI; 0.18–0.76) to predict satisfaction with HIV treatments. Nearly all of the FSWs 222 (91%) preferred the injectable ART over the conventional oral regimen at a duration of every 4 weeks. Finding from this study revealed that HIV treatment satisfaction was influenced by age at HIV diagnosis and commencement of sex work, education, marital status, HIV regimen and disclosure of HIV status. While the patients preferred the injectable ART over the conventional oral regimen. In view of these, targeted interventions should be focused on these factors

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Study Instrument and Data Collectionmentioning

confidence: 99%

HIV Treatment Satisfaction and Preferences for HIV regimen among Female Sex Workers

Haiwa,

Hedima,

Kalu

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…A large survey of 553 people with HIV and 450 physicians in the US and Canada showed that 59% of people with HIV and 55-66% of physicians would prefer/recommend a long-acting injectable to overcome treatment challenges such as daily pill burden and adherence. 30 The real-world effectiveness of DTG/3TC 2DR in individuals aged ≥65 years old has been assessed in two recent observational studies. Among 112 individuals ≥65 years of age starting DTG/3TC 2DR in Northern Italy (6 ART-naïve, 106 ART-experienced), 93% had an undetectable viral load at end of follow-up.…”

mentioning

confidence: 99%

Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care

Pierone Jr,

Brunet,

Fusco

et al. 2024

HIV

View full text Add to dashboard Cite

Two-drug regimens (2DR) may address drug-drug interactions and toxicity concerns. Dolutegravir/lamivudine (DTG/3TC) 2DR was approved in the US for both treatment-naïve and treatment-experienced individuals with a viral load <50 copies/mL. This study describes real-world DTG/3TC 2DR treatment outcomes among treatment-experienced individuals, stratified by age, sex, and race. Methods: From the OPERA ® cohort, people with HIV with a viral load <50 copies/mL who switched from a commonly used threedrug regimen to DTG/3TC 2DR as per the label between April 8, 2019 and April 30, 2021 were included. Incidence rates (Poisson regression) for loss of virologic control (first viral load ≥50 copies/mL), confirmed virologic failure (2 viral loads ≥200 copies/mL or discontinuation after 1 viral load ≥200 copies/mL), and DTG/3TC 2DR discontinuation were estimated overall and stratified by age, sex, and race. Results: The 787 individuals included were followed for a median of 13.6 months (IQR: 8.2, 22.3). Confirmed virologic failure occurred in ≤5 individuals. Loss of virologic control occurred at a rate of 14.0 per 100 person-years (95% CI: 11.7, 16.8). DTG/3TC 2DR discontinuation occurred at a rate of 17.5 per 100 person-years (95% CI: 15.0, 20.3); 4% discontinued for treatment-related reasons (viremia, adverse diagnosis, side effect, lab abnormality). For all outcomes, incidence rates were comparable across strata of age, sex, and race. Conclusion: This descriptive study demonstrates that DTG/3TC 2DR is an effective and well-tolerated treatment option for people with HIV with a viral load <50 copies/mL at switch, regardless of their age, sex, or race.

show abstract

Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

Moreno,

Izquierdo,

Alejos

et al. 2024

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada

Cited by 6 publications

References 22 publications

HIV Treatment Satisfaction and Preferences for HIV regimen among Female Sex Workers

HIV Treatment Satisfaction and Preferences for HIV regimen among Female Sex Workers

Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care

Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

Contact Info

Product

Resources

About